Antiviral Interferons Flashcards
Antiviral Interferons
Pegylated interferon-α 2a, 2b
Interferon-α 2a, 2b
Interferons are normal human cytokines that are used by the immune system to activate cells when infection is present, fight cancerous cells and perform other functions
Given for many diseases (like MS, cancer, viral hepatitis)
This class has been used for viral hepatitis B and C; now only pegylated forms recommended
Antiviral Interferons MOA
Have multiple MOA
Have direct antiviral effects, change cellular differentiation, inhibit cell growth, activate macrophages, increase lymphocyte cytotoxicity
Pegylated forms have PEG attached to the interferons; improve their PK by increasing half lives (allowing for decreased administration frequency)
Antiviral Interferons Spectrum
Alpha interferons used for HBV and HCV infections
Antiviral Interferons Adverse Effects
Very common; lead to noncompliance, dropout, and avoidance of use
Flu-like symptoms (most common): HA, fatigue, weakness, fever, myalgia
Depression is common; requires pharmacologic treatment
Do not give if patient has suicidal ideation
Anxiety can occur
Hematologic effects (notably cytopenias): neutropenia, anemia, thrombocytopenia In treatment of HCV, ribavirin usually primary cause of anemia
Can worsen decompensated cirrhosis; generally not recommended to these patients
Antiviral Interferons Important Facts
Pegylated: once weekly, less adverse effects, efficacy is similar or somewhat higher
Non-pegylated: three times weekly
Dosing varies significantly by agent and indication
For HCV, ribavirin differs for each form as well
For HCV: the two pegylated forms are equivalent but dosing differs
2a: fixed dose
2b: doses by weight
For HBV: only 2a has FDA indication but 2b has been studied
Interferons commonly cause it exacerbate depression; contraindicated in severe depression and suicidal patients
No rush for chronic HCV, so make sure depression is controlled before starting
For HBV, other drugs are better options for depressed patients
Antiviral Interferons Good For
Use for HCV has declined due to advent of new direct acting antiviral agents
For chronic HBV, nucleoside/tide analogs preferred due to better adverse effect profile but are taken indefinitely compared to finite regimen for interferon